Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA6 | P23280 | 5/20 | 0.42 |
| ▸ | CA7 | P43166 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA5A | P35218 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CA3 | P07451 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9437143 | 1.00 | CA12 (0.42) | CA12CA6CA7CA9CA14 | |
| SCHEMBL770197 | 0.97 | CA12 (0.44) | CA12CA6CA7CA9CA14 | |
| SCHEMBL8874005 | 0.92 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL10151431 | 0.88 | MEN1 (0.50) | CA12CA6CA7CA9CA14 | |
| SCHEMBL14980618 | 0.88 | TSHR (0.42) | CA12CA6CA7CA9CA14 | |
| SCHEMBL19189861 | 0.88 | MEN1 (0.50) | CA12CA6CA7CA9CA14 | |
| SCHEMBL8330702 | 0.88 | KDM4E (0.41) | CA12CA6CA7CA9CA14 | |
| SCHEMBL18593493 | 0.88 | KDM4E (0.49) | CA12CA6CA7CA9CA14 | |
| SCHEMBL13520206 | 0.88 | TSHR (0.38) | CA12CA6CA7CA9CA14 | |
| SCHEMBL13736532 | 0.86 | CA12 (0.44) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11181521-B2 | Intra-droplet surface engineering to capture a molecular target | UNIVERSITE DE STRASBOURG (FR) | 2021-11-23 | — | — | US | disclosed |
| EP-3736572-A1 | INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET | Université de Strasbourg (FR) | 2020-11-11 | — | — | EP | disclosed |
| EP-3440463-B1 | INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET | UNIV STRASBOURG (FR) | 2020-07-08 | — | — | EP | disclosed |
| US-20190113509-A1 | INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-18 | — | — | US | disclosed |
| WO-2017174610-A1 | INTRA-DROPLET SURFACE ENGINEERING TO CAPTURE A MOLECULAR TARGET | UNIVERSITE DE STRASBOURG (FR) | 2017-10-12 | — | — | WO | disclosed |
| US-20120189601-A1 | ASSISTED ENZYME REPLACEMENT THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-20120189601-A1 | ASSISTED ENZYME REPLACEMENT THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | CA12 1525/4885CA6 454/4885CA7 917/4885 |
| US-20120189601-A1 | ASSISTED ENZYME REPLACEMENT THERAPY | GAA, GLA, ENPEP | CA12 1046/4885CA6 1157/4885CA7 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.